You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Armistice Capital | 0 | 29,609,938 | 0 | 29,609,938 | 29,609,938 | 73.5% |
| Armistice Capital Master Fund, Ltd | 0 | 29,609,938 | 0 | 29,609,938 | 29,609,938 | 73.5% |
| Steven Boyd | 0 | 29,609,938 | 0 | 29,609,938 | 29,609,938 | 73.5% |
Follow Steven Boyd's Armistice Capital
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 10 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No.2)*
| Cerecor Inc. |
| (Name of Issuer) |
| Common Stock, $0.001 par value |
| (Title of Class of Securities) |
| 15671L109 |
| (CUSIP Number) |
| Tohuan Steve Chen c/o Armistice Capital LLC 510 Madison Avenue 22nd Floor New York, NY 10022 Telephone Number: 212-231-4930 |
| (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
| June 30, 2017 |
| (Date of Event Which Requires Filing of this Statement) |
| If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d‑1(f) or 240.13d-1(g), check the following box [_]. | |
| * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. | |
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 10
